InnolandBio (Suzhou) was founded in 2021 and is mainly engaged in pre-clinical CRO service. The predecessor of InnolandBio (Suzhou) was the Cardiovascular and Metabolic Diseases Department of CrownBio Ltd. The very same team has 13 years of experience in pre-clinical pharmacological efficacy and toxicological evaluation, especially in the field of cardiovascular and metabolic diseases, and has been well recognized by world-renowned pharmaceutical companies. InnolandBio (Suzhou) now has the world’s largest cohort of non-human primates with spontaneous metabolic diseases, and has established various animal models of diabetes and the related complications, such as eye diseases and aging related diseases, etc. InnolandBio is dedicated to continuously providing top quality service to the global pharmaceutical research and development.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
